Search Result

Results for "

HER2-targeting

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Payload (2) Akt (1) Antibody-Drug Conjugates (ADCs) (6) Apoptosis (1) Drug-Linker Conjugates for ADC (4) EGFR (14) ERK (1) PARP (1) Reference Standards (1) Topoisomerase (3)
By Research Areas:	Cancer (21)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13631D

DXd Maximum Cited Publications 14 Publications Verification Exatecan derivative for ADC	Topoisomerase ADC Payload	Cancer
DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC₅₀ of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).

HY-P9921

Trastuzumab emtansine 5+ Cited Publications Ado-Trastuzumab emtansine; PRO132365; T-DM 1	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer ^[2].

HY-P9921A

Trastuzumab emtansine (solution) 5+ Cited Publications Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer ^[2].

HY-13631DS

DXd-d5 Exatecan-d₅ derivative for ADC	Topoisomerase ADC Payload	Cancer
DXd-d₅ is a deuterium labeled DXd. DXd is a potent DNA topoisomerase I inhibitor, with an IC₅₀ of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .

HY-164202

ORM-5029	Antibody-Drug Conjugates (ADCs)	Cancer
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 exhibits robust efficacy across 14 HER2-positive breast cancer cell lines, with IC₅₀ values ranging from 0.3 to 14.4 nM.ORM-5029 demonstrates anti-tumor activity in the BT474 xenograft model. ORM-5029 can be used for study of breast cancer ^[2] .

HY-101982

Lys-SMCC-DM1 1 Publications Verification Lys-Nε-MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a *HER2*-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer ^[2].

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

HY-164762

Trastuzumab rezetecan SHR-A1811	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab rezetecan (SHR-A1811) is a *HER2*-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-P991238

MEDI4276 Antibody	ADC Antibody EGFR	Cancer
MEDI4276 Antibody is an *HER2*-targeted antibody, which can be used for the synthesis of the ADC molecule MEDI4276. MEDI4276 Antibody can be used in the study of cancer .

HY-P99630

Gancotamab antibody MM-302 antibody	EGFR	Cancer
Gancotamab antibody (MM-302) is a *HER2*-targeted antibody with antitumor activity .

HY-164763

SHR-A1201	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
SHR-A1201 is a *HER2*-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a *HER2* targeting peptide that binds to *HER2* to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-176976

Exatecan-mpGNNG	Drug-Linker Conjugates for ADC	Cancer
Exatecan-mpGNNG (Compound 10a) is the linker-payload component of an antibody-drug conjugate (ADC). Exatecan-mpGNNG is composed of Exatecan (HY-13631), a potent topoisomerase I inhibitor, and the linker .

HY-P10648

Herceptide HER2-targeting peptide	EGFR	Cancer
Herceptide (HER2-targeting peptide) is a *HER2*-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .

HY-168285

LE01	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
LE01 is a drug-linker conjugate for ADC. LE01 contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D). LE01 can be used to synthesize HER2-targeting ADC (HER2-LE01) .

HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .

HY-P11760

HER2-targeted peptide H10	EGFR	Cancer
HER2-targeted peptide H10 is a *HER2*-targeting peptide with a K_d value of 30.4 nM. HER2-targeted peptide H10 specifically accumulates in *HER2*-positive tumor tissues of xenograft mice, when conjugated with nanoparticles. HER2-targeted peptide H10 can be used for studies related to *HER2*-positive breast cancer .

HY-P991977

BSI-001 5G9	EGFR Apoptosis PARP Akt ERK	Cancer
BSI-001 (5G9) is a *HER2*-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of *HER2*-positive breast cancer and *HER2*-overexpressing gastric cancer .

HY-P11761

HYNIC-H10F	EGFR	Cancer
HYNIC-H10F is a conjugate of HER2-targeting peptide H10F and bifunctional chelator HYNIC. HYNIC-H10F can be used in breast cancer-related research .

HY-P11613

DOTA-WC8	EGFR	Cancer
DOTA-WC8 is a *HER2*-targeting peptide probe with a K_D of 61.20 nM. ⁶⁸Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .

HY-101982R

Lys-SMCC-DM1 (Standard) Lys-Nε-MCC-DM1 (Standard)	Reference Standards Drug-Linker Conjugates for ADC	Cancer
Lys-SMCC-DM1 (Standard) is the analytical standard of Lys-SMCC-DM1 (HY-101982). This product is intended for research and analytical applications. Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a HER2-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer ^[2].

HY-P11590

WGYRGFYC	EGFR	Cancer
WGYRGFYC (WC8) is a selective *HER2*-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

Cat. No.	Product Name	Type

HY-P9921A

Trastuzumab emtansine (solution) 5+ Cited Publications Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)	Fluorescent Dyes
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer ^[2].

Trastuzumab emtansine (solution)

5+ Cited Publications

Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)